You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Novel SCD1 inhibitors for treatment of cancer

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Dual View Endoscopy for Colonoscopy

    SBC: Omniscient Imaging, Inc.            Topic: 102

    AbstractAn estimatedmillion colonoscopies are performed annually in the US at a cost of about $Bhowever current colonoscopes with forward vision fail to detectof precancerous polypsOverof the missed polyps are located on or behind numerous folds in the colon where they are hidden from the sight of a forward view colonoscopeIn this research proposalwe propose to complete our development of an imagi ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples

    SBC: CIRCA BIOSCIENCE, LLC            Topic: 102

    Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil

    SBC: AcePre, LLC            Topic: NCCIH

    PROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Robust Predictor of Colon Cancer Risk

    SBC: Morgan and Mendel Genomics, Inc.            Topic: 102

    Summary At leastpeople in the United States are at high risk for Lynch syndromebased on inheritance of a genetic mutation in the mismatch repairMMRor double strand breakDSBrepair pathwayMore than half of them are unaware of their riskbecause their family history is uninformative or unknownGenetic testing is important for identifying mutations in this pathwaybut in a large number of cases no mutati ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. DNA Quadruplex Control of hTERT Transcription: A New Therapy for Taxotere Resistant Prostate Cancer

    SBC: Reglagene, LLC            Topic: 102

    PROJECT SUMMARYTelomerase maintains telomere length and prevents cellular senescenceIt is upregulated inof cancerssuppressed in most non cancer tissuesand is a primary driver of tumor cell immortalityNo clinical agent acting on telomerase has been approved for human useA hurdle for approaches that directly inhibit the action of telomerase is that therapeutic effect is observed only after many popu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Preclinical studies of Selective and Orally Bioavailable Aurora B Inhibitors for the Treatment of AML

    SBC: SYNACTIX PHARMACEUTICALS, INC.            Topic: 102

    ABSTRACTThe Aurora Kinase FamilyAKFcomprises heavily pursued therapeutic targets for cancer because of their intimate involvement in cell division and tumor progressionNumerous therapeutic campaigns have been initiated against the AKFwith promising clinical successes emanating from strategies targeting either Aurora A or Aurora BHoweverthe US Food and Drug Administration has yet to approve a cance ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Targeted Nanotherapy to Donor Organ Endothelia Modulates Early Immune Responses and Protects Against Late Graft Failure

    SBC: ToleRaM NanoTech LLC            Topic: NIBIB

    ABSTRACT Transplantation is an accepted and highly successful therapy for end stage organ diseaseWhile success rates and survival have risen steadilydue largely to improved immunosuppression regimesthere is a growing appreciation that damage and inflammation that occur early in the life of the graftsignificantly impact chronic rejection and thus long term survivalCentral to these early event injur ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government